Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet disease with pulmonary involvement

Agnès Hamzaoui,1,2,* Hanene Chelbi,2 Fayçal Hai Sassi2 and Kamel Hamzaoui2

1Abderrahmen Mami Hospital; Ariana, Tunisia; 2Medicine Faculty of Tunis; University El Manar; Tunis, Tunisia

Key words: B cell-activating factor of the TNF family, Behçet disease, IL-6, IL-13, bronchoalveolar lavage

Introduction

Behçet disease (BD) is a multi-system inflammatory disorder, currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been considered. There have been ongoing efforts to elucidate the aetiology of BD. Many studies have investigated genetic aspects and immunologic features of the disorder. However, there is certainly a need for more prospective, controlled and longitudinal studies—not an easy endeavour considering the heterogeneity of BD. Immunological studies were needed particularly in inflammatory sites as the lung. The International Study Group for Behçet Disease has established diagnostic criteria for BD, which make recurrent oral ulcers a mandatory finding, along with two of the four: recurrent genital ulcers, eye involvement, skin lesions and pathergy.1 While various tissue types such as blood vessel, eye, skin, mucosa, joint or central nervous system (CNS), may be affected during the course of BD, lung involvement, remains one of the most serious complications of the disease.2 Large vessel vasculitis in BD may affect the pulmonary arteries, the aorta and other major peripheral vessels.3-6

Pulmonary artery aneurysms, arterial and venous thrombosis, pulmonary infarction, recurrent pneumonia, bronchiolitis obliterans organized pneumonia, and pleurisy are the main features of pulmonary involvement in Behçet disease. The objective of this study was to investigate the production of B-cell-activating factor of the TNF family (BAFF), an important regulator of B-cell survival and immunoglobulin class-switch recombination, in bronchoalveolar lavage (BAL) fluid from BD patients having pulmonary manifestation. Bronchoalveolar lavage (BAL) was performed in 15 BD patients with pulmonary manifestation and 18 BAL from healthy controls. Concentrations of B-cell-active cytokines, including BAFF, IL-6 and IL-13, were measured by using specific ELISA and cytometric bead array assays. Levels of BAFF protein were significantly increased in BAL fluid from active BD (109 ± 21.78 pg/mL; p < 0.0001) compared with those of healthy controls (4.83 ± 1.75 pg/mL; p < 0.0001). In the BAL fluid, BAFF levels were significantly correlated with absolute numbers of total cells (r = 0.823; p < 0.0001), lymphocytes (r = 0.709; p < 0.0001), neutrophils (r = 0.809; p < 0.0001) and macrophages (r = 0.742; p < 0.0001). Normalization to albumin indicated that BAFF production occurred locally in the airways. BAFF levels were also significantly correlated with the other B-cell-activating cytokines IL-6 (r = 0.882, p < 0.001) and IL-13 (r = 0.659, p < 0.001).

The antigen-induced production of BAFF in the lung of active BD with pulmonary manifestations might contribute to immunoglobulin synthesis by B-cells. The cells residing in the lung might affect each other through BAFF.

BAFF has been recognized to mainly be a product of myeloid cells, such as monocytes, macrophages, dendritic cells (DCs) and neutrophils.7,8 In airway inflammatory diseases local B-cell class-switch recombination can mediate activation of airways in response to antigen exposure.9,10 B-cell-activating factor of the TNF family (BAFF, also known as BLYS, TNFSF13B, TALL-1 and THANK) is a member of the TNF superfamily that plays important roles in B-cell survival, proliferation and maturation.11 BAFF binds to 2 high-affinity receptors that are selectively expressed on B-cells, including BAFF receptor and transmembrane activator and CAML interactor (TACI). BAFF can also bind to a low-affinity receptor, B-cell maturation antigen.12 Recently, it has been reported that BAFF is produced by bronchial epithelial cells and nasal epithelial cells.13

In the present study we investigated BAFF expression in the bronchoalveolar lavage (BAL) of active Behçet disease patients with pulmonary involvement. We report also correlations between BAL-BAFF levels and cell counts and that the levels of production were highly correlated with the appearance of the other B-cell-activating cytokines IL-6 and IL-13.
Table 1. Clinical features of patients with Behçet disease (BD) with pulmonary involvement

<table>
<thead>
<tr>
<th>Lesions</th>
<th>Number of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral ulcer</td>
<td>15 (100%)</td>
</tr>
<tr>
<td>Genital ulcer</td>
<td>15 (100%)</td>
</tr>
<tr>
<td>Eye lesions</td>
<td>10 (66%)</td>
</tr>
<tr>
<td>Skin lesions (erythema nodosum, folliculitis, …)</td>
<td>8 (53.3%)</td>
</tr>
<tr>
<td>Arthritis</td>
<td>15 (100%)</td>
</tr>
<tr>
<td>Vascular symptoms</td>
<td>12 (80%)</td>
</tr>
</tbody>
</table>

Overall burden of the disease manifestations in BD patients is described. Patients received colchicine, steroids/cyclosporine. The pulmonary arteries are the second most common site of arterial involvement, preceded by the aorta. Aneurysms are more common than thrombosis.1

Subject characteristics and inflammatory cells responses in BAL fluid. BAL fluids were collected from 15 subjects with BD and 18 healthy controls (Table 1). Recovery of BAL fluid did not differ between healthy controls (median, 42%; range, 16% to 79%) and active BD (median, 48%; range, 19% to 82%). As we expected, total BD-BAL cell numbers, lymphocytes, macrophages and neutrophils, were increased in significant numbers in active BD (Table 2).

Detection of BAFF in BAL fluid. Figure 1 depicts the ELISA results for BAFF. BAFF level were less than the limit of detection in 4/15 BAL from BD patients. In the 11 other patients BAFF protein levels were significantly increased (median, 53.8 pg/mL; range, 0–407.4 pg/mL) compared to values obtained in healthy controls (p = 0.001).

BAFF is known to circulate in the blood, and serum levels in active BD have been reported in the range of 190 to 440 pg/mL.14 To elucidate whether an increase of BAFF protein levels in BAL fluid reflects local production in the airway or whether it reflects plasma leakage, we measured the concentration of albumin and used it as a marker of plasma exudation.

Albumin concentrations in BAL fluid were significantly increased in active BD (0.40 mg/mL; range, 0.08–2.96 mg/mL) compared to BAL from healthy controls (0.030 mg/mL; range, 0.010–2.030 mg/mL). When we normalized the concentration of BAFF to the concentration of albumin in BAL fluid and serum, the BAFF concentration in BAL fluid of BD patients (314.49 ± 415 pg/mg albumin) was still significantly higher than in BAL fluid from healthy controls (37.71 ± 88.40 pg/mg albumin; p = 0.0096; Fig. 1B). BAL-BAFF levels normalized to albumin still expressed at lower levels when compared with levels in sera (6101.3 ± 1831.82 pg/mg albumin; p = 0.0001). These data suggested that BAFF is released in the airways.

Levels of BAFF correlate with inflammatory cells and cytokines. In the BD-BAL fluid, BAFF levels were strongly correlated with absolute numbers of total cells (r = 0.823, p = 0.001) (Fig. 2A), lymphocytes (r = 0.709, p = 0.001) (Fig. 2C), macrophages (r = 0.742, p = 0.001) (Fig. 2B) and neutrophils (r = 0.809, p = 0.001) (Fig. 2D).

We also analyzed the concentrations of the other B-cell-activating cytokines IL-6 and IL-13 in the BAL fluid and in the serum. Confirming previous reports,15,17 we observed that the concentrations of IL-6 and IL-13 were significantly increased in serum from BD patients (Fig. 3A–C).

B-cell-activating cytokines in BAL fluid from active BD patients were expressed at higher levels than in BAL-fluid from healthy controls [IL-6: 99.0 pg/ml (17.80–125.0); IL-13: 109.0 pg/ml (37.5–159.0)] when compared to healthy-BAL fluid [IL-6: 9.30 pg/ml (4.0–33.0); IL-13: 3.0 pg/ml (0.0–12.0)] [p < 0.0001] (Fig. 3A). Using BAL fluid data obtained from BD patients, we found that the levels of BAFF were strongly correlated with the levels of IL-6 (r = 0.882, p < 0.001) (Fig. 3B) and IL-13 (r = 0.659, p < 0.0001) (Fig. 3C).

Discussion

BAFF is an important regulator of B-cell activation, proliferation and immunoglobulin production.8 This study provides the first demonstration that levels of BAFF, as well as the other B-cell-activating cytokines IL-6 and IL-13, were significantly increased in BAL fluid of BD patients with pulmonary involvement. The concentrations of BAFF detected in BAL fluid were highly correlated with the absolute numbers of recruited inflammatory cells, including lymphocytes, macrophages and neutrophils. The concentrations of antigen-induced BAFF were also correlated with the concentrations of the other B-cell-active cytokines IL-6 and IL-13. BAFF and BAFF mRNA were recently studied in BD, in the peripheral circulation, in skin lesion and in the central nervous system.14,18

Pulmonary aneurysms represent the major complication of pulmonary Behçet disease and have a poor prognosis, being associated with massive haemoptysis. In situ pulmonary artery thrombus can lead to pulmonary infarction. Superior vena cava thrombosis progresses slowly, allowing the development of a prominent collateral circulation. Vascular inflammation can spread to the mediastinum, the pleura and the lungs with diffuse pulmonary haemorrhages, bronchiolitis and organising pneumonia. Electron beam tomodensitometry and MRI are the best diagnostic techniques for assessing pulmonary vascular lesions.3,4 Treatment of vasculitis in BD should be based on the type of vascular disease and may vary among different types of vascular disease.

In the current study we present the first evidence that BAFF levels are significantly increased in BAL fluid from BD patients. To eliminate the possibility that the result merely reflects vascular leakage, we normalized values to the concentration of albumin as an indicator of plasma leak. Normalized BAFF concentrations in BAL fluids were still significantly higher than those in BAL fluids of healthy controls. Serum BAFF levels were more increased in BD than in BAL fluid. Our results suggested that BAFF is produced locally in the lower airway of active BD. These results do not totally eliminate the possibility that vascular leakage or active transport contribute to the increased appearance of...
This study provides the first demonstration that IL-13 levels were significantly increased in BD-BAL fluid. Contradictory results were reported in serum-IL-13 level in BD. Increased IL-13 (Th2) levels were reported in active BD, which contrasted with results from Raziuddin et al. We think that Th1/Th2 cytokines production is dependent on the inflammatory site. The presence of IL-13 in BAL from BD patients with pulmonary involvement could be partially explained by allergic inflammation considering the greater importance of IL-13 in the effector phase of allergic airway disease. The prevalence of Th2 cell-mediated diseases, such as atopic diseases, has been noted to be low in Th1-cell-mediated diseases. Blood eosinophil count and serum total IgE levels were found low in BD patients compared to allergic bronchial asthma. However, high IgE levels were detected in certain patients with BD as in patients with bronchial hyperactivity.

Table 2. Inflammatory cells in bronchoalveolar lavage (BAL) fluid from Behçet disease (BD)

<table>
<thead>
<tr>
<th></th>
<th>Control subjects</th>
<th>Behçet’s disease</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cells (10⁶ cells)</td>
<td>10.2 (9.4–21.6)</td>
<td>18.5 (10.9–42.0)</td>
<td>0.001</td>
</tr>
<tr>
<td>Macrophages (10⁶ cells)</td>
<td>9.8 (7.5–22.8)</td>
<td>16.9 (10.52–42.5)</td>
<td>0.001</td>
</tr>
<tr>
<td>Lymphocytes (10⁶ cells)</td>
<td>0.8 (0.4–5.8)</td>
<td>4.7 (1.9–22.8)</td>
<td>0.001</td>
</tr>
<tr>
<td>Neutrophils (10⁶ cells)</td>
<td>0.9 (0.0–6.8)</td>
<td>2.6 (0.9–21.5)</td>
<td>0.001</td>
</tr>
<tr>
<td>Eosinophils (10⁶ cells)</td>
<td>0.1 (0.0–1.2)</td>
<td>0.1 (0.0–1.5)</td>
<td>0.92</td>
</tr>
</tbody>
</table>

Values are presented as median (ranges). *Significance Behçet disease versus control subjects. BAL samples from 15 BD patients with pulmonary involvements and 18 healthy controls were investigated. Aliquots of fluid were removed for measurement of cell counts with a hemocytometer, cell viability was determined by means of trypan blue dye exclusion. Patients with BD exhibited increased values of total cell count in their BAL when compared to healthy controls. Significant differences were also observed. Macrophages, lymphocytes and neutrophils were present in significant numbers in BAL from BD patients.

BAFF in antigen-challenged airways. IL-6 and IL-13 were also produced locally and their concentrations were strongly correlated with concentrations of BAFF. Collectively, these data suggest that local production of the B-cell-stimulating cytokines BAFF, IL-13 and IL-6 might play a role in local B-cell responses in the lower airways of patients with allergic inflammatory diseases.

Deregulated production of interleukin-6 (IL-6) has been found in several inflammatory/autoimmune disorders. Increased IL-6 levels have been reported in sera and in peripheral blood mononuclear cells of BD patients. In a recent study, IL-6 level was found increased in another inflammatory site: the CNS. IL-6 in CSF from BD predicted the long-term outcome of the patients. Some studies have found a correlation between serum IL-6 levels and disease activity.

This study provides the first demonstration that IL-13 levels were significantly increased in BD-BAL fluid. Contradictory results were reported in serum-IL-13 level in BD. Increased IL-13 (Th2) levels were reported in active BD, which contrasted with results from Raziuddin et al. We think that Th1/Th2 cytokines production is dependent on the inflammatory site. The presence of IL-13 in BAL from BD patient with pulmonary involvement could be partially explained by allergic inflammation considering the greater importance of IL-13 in the effector phase of allergic airway disease. The prevalence of Th2 cell-mediated diseases, such as atopic diseases, has been noted to be low in Th1-cell-mediated diseases. Blood eosinophil count and serum total IgE levels were found low in BD patients compared to allergic bronchial asthma. However, high IgE levels were detected in certain patients with BD as in patients with bronchial hyperactivity.
BD patients with pulmonary involvement were positively correlated with the numbers of macrophages, lymphocytes and neutrophils but not eosinophils. This suggests that infiltrating macrophages, lymphocytes and neutrophils might play a greater role in BAFF production in the airways.

Recently, it has been reported that BAFF levels are increased in nasal polyp tissue from patients with chronic rhinosinusitis and in the upper airway include mucosal epithelial cells and this result may probably reflect nonspecific inflammation which is seen in BD.  

We did not identify the origins of BAFF production in the lower airways. It is well known that BAFF is produced by monocytes, macrophages, DCs, neutrophils and epithelial cells from several tissues, including lung. Several groups have reported that T and B lymphocytes are capable of producing BAFF. Our present study showed that BAFF concentrations in BAL fluid of BD patients with pulmonary involvement were positively correlated with the numbers of macrophages, lymphocytes and neutrophils but not eosinophils. This suggests that infiltrating macrophages, lymphocytes and neutrophils might play a greater role in BAFF production in the airways.

Recently, it has been reported that BAFF levels are increased in nasal polyp tissue from patients with chronic rhinosinusitis and in the upper airway include mucosal epithelial cells and this result may probably reflect nonspecific inflammation which is seen in BD.
unidentified infiltrating cells in the lamina propria and in BAL from asthmatics. This suggests that overproduction of BAFF contribute to the inflammation through expansion and activation of B-cells. This would support the suggestion that both infiltrating cells in BAL fluid and tissue epithelial cells might produce BAFF in the lower airways. In either case the correlation of local BAFF production with the influx of inflammatory cells suggests that BAFF production is an integral part of the inflammatory response. Future studies will be required to determine the precise nature of the BAFF-producing cells in the lung from BD patients with pulmonary involvement.

In summary, we report here that BAFF is upregulated in the BAL from BD patients with pulmonary involvement. BAFF levels were highly correlated with levels of IL-13 and IL-6. Our findings indicate that BAFF and other B-cell-stimulating cytokines are produced locally in the BAL and might contribute to local B-lymphocyte responses in airway inflammatory BD and in host defense. These results suggest that BAFF and its signaling in B-cells contribute to B-cell abnormalities and the development of pulmonary manifestation in patients with BD. Production of BAFF in inflammatory sites might have either a protective or pathogenic role in immunity.

Methods

Patients. We studied 15 active BD patients (14 males and 1 female; nonsmoking patients; mean age: 47.5 years; range: 32–56 years). They were selected on the basis of the criteria defined by the International Study Group for diagnosis of Behçet disease. Clinical features of the patients with active stage are given in Table 1, which describe overall burden of the disease manifestations in BD patients. All active BD patients have pulmonary manifestations. Active BD patients were always treated with steroids and colchicine. The control subjects consisted of 18 nonsmokers (16 men and 2 women; mean age: 45.4 years; range: 37–45 years) undergoing routine investigations for suspected bronchial carcinoma and whose chest X-ray (CXR), bronchial examination, and pulmonary functions were normal. None of them had evidence of acute infection or chronic disease (e.g., other autoimmune or atopic disorders). Informed consent was obtained from all of
the patients and control subjects. The design of the study was approved by our National Ethics Committee.

Bronchoalveolar lavage. Bronchoscopy was performed according to standard guidelines, as described previously. Thirty minutes prior to the procedure patients received 0.5 mg of atropine and 12.5 mg codeine intramuscularly. Local anaesthesia of the oropharynx was achieved by Novesine spray (Wander, Switzerland) until gag reflexes subsided. Bronchoscopy was performed using a Pentax bronchoscope through which 150 ml of normal prewarmed saline in aliquots of 20 ml were instilled into a subsegment of the right middle lobe. BAL fluid was then immediately aspirated by gentle hand suction into plastic tubes and kept at 4°C on ice.

Processing of BAL cells. BAL samples were filtered through a two-layer sterile gauze into sterile plastic vials (Falcon, Oxnard, CA), centrifuged at 4°C and 500 g for 10 minutes. The supernatant was removed and cells were washed twice in PBS. The total cell number was counted using a Neubauer hemocytometer (Brand, Wertheim, Germany). Differential cell counts were performed after Giemsa staining (Merck, Darmstadt).

Cell counts. The volume of fluid recovered from each 100-mL lavage specimen was recorded. Before centrifugation, aliquots of fluid were removed for measurement of cell counts with a hemocytometer, cell viability was determined by means of trypan blue dye exclusion, and differential cell counts were obtained by using a Diff-Quik stain (American Scientific Products, McGaw Park, IL) of cytocentrifuge preparations (Cytospin; Shandon Southern Instruments, Inc., Sewickley, PA), as previously described.

Total cells were calculated as the volume of BAL fluid recovered multiplied by cells per millilitre by hemocytometer count. Total counts of each cell type were calculated as total cells multiplied by the percentage of each cell type determined by differential cell counts.

Soluble protein measurement. The concentrations of BAFF (R&D Systems, Minneapolis, MN), albumin (Bethyl Laboratory, Montgomery, TX), IgA (Bethyl Laboratory), and sIgA (ALPCO Diagnostics, Salem, NH) in BAL fluids were measured with specific ELISA kits as we have recently reported. The minimal detection limits for BAFF is 31 pg/mL.

The concentrations of albumin (Bethyl Laboratory, Montgomery, Tex), IgA (Bethyl Laboratory), and sIgA (ALPCO Diagnostics, Salem, NH) in BAL fluids were measured with specific ELISA kits. The minimal detection limits for these kits are 6.25 ng/mL, 7.8 ng/mL and 22.2 ng/mL, respectively. The concentrations of IL-6, IL-17 and MMP-9 in BAL fluids were measured by using a cytometric bead array (CBA) human IL-6 Flex Set. In brief, 50 µL of the mixed capture beads and 50 µL of BAL fluid were incubated for 1 hour at room temperature. After adding 50 µL of the phycoerythrin detection reagent to the mixture and incubation for 2 hours at room temperature, the beads were then washed with the wash buffer and analyzed with a BD FACSArray Bioanalyzer (BD Biosciences). The CBA data were analyzed with FCAP Array software version 1.0.1 (BD Biosciences). The minimal detection limits are 5 pg/mL (IL-6), 5 pg/mL (IL-13) and 1 ng/mL (IgE).

Statistical analysis. All data are reported as medians (ranges, minimum to maximum). Differences between groups were analyzed by using the Wilcoxon signed-rank test or the Mann-Whitney U test. Correlations were assessed by using Spearman rank correlation. A p value of less than 0.05 was considered significant.

Acknowledgements

Our unit research (Homeostasis and Cell Dysfunction: 99/UR/08-40) had the financial support of “High Education Ministry of Science and Research of Tunisia.” The authors wish to thank Nezha Ben Hamida (Anatomopathology department, Institute of Cancérology) for her technical assistance.

This study was supported by grant from the: “Ministère de l’Enseignement Supérieur de la Recherche Scientifique et


27. Evereklioglu C, Er H, Turkov Y, et al. Serum levels of TNFalpha, sIL-2R, IL-6 and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease. Mediators Inflamm 2002; 11:87-93.


